The objectives of this study were to evaluate sex-related demographic and clinical characteristics of CML patients in Azerbaijan, compare imatinib response and survival outcomes between male patients and female patients, assess molecular differences including ABL kinase domain mutations and CYP polymorphisms, and provide a regionally specific analysis to determine whether sex should be considered a relevant factor in CML prognosis and management. This evidence concerns the gene PPIG and chronic myelogenous leukemia, BCR-ABL1 positive.